Back to results

Massachusetts Institute of Technology

Improving the delivery and efficacy of a cancer therapeutic via extracellular matrix modification

Abstract

dc:description.abstract

The extracellular matrix (ECM) has been shown to be a significant source of hindrance to the transport of macromolecules in solid tumors. This thesis shows that by limiting their interstitial transport, the tumor ECM can reduce the efficacy of cancer therapeutics. Furthermore, techniques for overcoming this transport barrier and improving the effectiveness of existing cancer therapetuics are developed. Mathematical modeling was utilized to characterize the distribution of a therapeutic herpes simplex virus (HSV) vector in solid tumors. The model showed that the spread of virus following intratumoral injection is severely limited by rapid binding and limited diffusion. Importantly, the model demonstrates that an improvement in virus diffusion can enhance its distribution significantly. In vivo multiphoton imaging of fibrillar collagen type I and injected HSV vectors largely supported the model predictions. Injected viral particles could not penetrate dense networks of fibrillar collagen. Both the initial distribution and subsequent propagation of these replication-competent vectors were limited by collagen. Degradation of tumor collagen with bacterial collagenase enhanced the distribution and efficacy of the virus. To develop a technique that is clinically applicable, human collagenases were screened for similar activity. Matrix metalloproteinase (MMP) -1 and -8 were identified as viable candidates and tested for their ability to degrade collagen and enhance diffusion in tumors. When overexpressed in tumors, neither MMP significantly altered collagen content or diffusive transport. However, these MMPs have multiple matrix substrates and were found to deplete the tumor of sulfated glycosaminoglycans (GAGs). This, in turn, increased the hydraulic conductivity of these tumors, enhancing the distribution and efficacy of infused oncolytic HSV. Genetic mutations were employed to enhance the activity of these enzymes, but impaired intracellular processing and inactivating autoproteolytic degradation reduced overall activity.

Degree

thesis:*
Department dc:contributor.department
Massachusetts Institute of Technology. Dept. of Chemical Engineering.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2008

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Mok, Wilson
Advisor dc:contributor.advisor
  • Rakesh K. Jain and Robert S. Langer.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/42430
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/42430

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
citation

Mok, Wilson. Improving the delivery and efficacy of a cancer therapeutic via extracellular matrix modification. Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/42430